These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 33655380

  • 1. The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial.
    Ogdie A, Walsh JA, Chakravarty SD, Peterson S, Lo KH, Kim L, Li N, Hsia EC, Chan EKH, Kavanaugh A, Husni ME.
    Clin Rheumatol; 2021 Sep; 40(9):3667-3677. PubMed ID: 33655380
    [Abstract] [Full Text] [Related]

  • 2. The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial.
    Reveille JD, Hwang MC, Danve A, Kafka S, Peterson S, Lo KH, Kim L, Hsia EC, Chan EKH, Deodhar A.
    Clin Rheumatol; 2021 Apr; 40(4):1331-1341. PubMed ID: 32926247
    [Abstract] [Full Text] [Related]

  • 3. Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients With Psoriatic Arthritis: 24-Week Results of the GO-VIBRANT Trial.
    Husni ME, Kavanaugh A, Chan EKH, Peterson S, Li N, Hsia EC, Kim L, Lo KH, Harrison DD, Han C.
    Value Health; 2020 Oct; 23(10):1286-1291. PubMed ID: 33032771
    [Abstract] [Full Text] [Related]

  • 4. The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.
    Curtis JR, McInnes IB, Rahman P, Gladman DD, Yang F, Peterson S, Agarwal P, Kollmeier AP, Hsia EC, Han C, Shiff NJ, Shawi M, Tillett W, Mease PJ.
    Adv Ther; 2022 Oct; 39(10):4632-4644. PubMed ID: 35947348
    [Abstract] [Full Text] [Related]

  • 5. The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial.
    Bingham CO, Weinblatt M, Han C, Gathany TA, Kim L, Lo KH, Baker D, Mendelsohn A, Westhovens R.
    J Rheumatol; 2014 Jun; 41(6):1067-76. PubMed ID: 24786931
    [Abstract] [Full Text] [Related]

  • 6. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.
    Kavanaugh A, McInnes IB, Krueger GG, Gladman D, Beutler A, Gathany T, Mack M, Tandon N, Han C, Mease P.
    Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1666-73. PubMed ID: 23666608
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial.
    Mease P, Husni ME, Kafka S, Chakravarty SD, Harrison DD, Lo KH, Xu S, Hsia EC, Kavanaugh A.
    Arthritis Res Ther; 2020 Mar 06; 22(1):43. PubMed ID: 32143685
    [Abstract] [Full Text] [Related]

  • 8. Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis.
    Curtis JR, McInnes IB, Rahman P, Gladman DD, Peterson S, Yang F, Adejoro O, Kollmeier AP, Shiff NJ, Han C, Shawi M, Tillett W, Mease PJ.
    Rheumatol Ther; 2024 Apr 06; 11(2):425-441. PubMed ID: 38386178
    [Abstract] [Full Text] [Related]

  • 9. Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial.
    Reveille JD, Deodhar A, Ince A, Chan EKH, Peterson S, Li N, Hsia EC, Kim L, Lo KH, Xu S, Harrison DD, Han C.
    Value Health; 2020 Oct 06; 23(10):1281-1285. PubMed ID: 33032770
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis.
    Husni ME, Kavanaugh A, Murphy F, Rekalov D, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC.
    Arthritis Care Res (Hoboken); 2020 Jun 06; 72(6):806-813. PubMed ID: 30980514
    [Abstract] [Full Text] [Related]

  • 11. Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study.
    Kavanaugh A, Husni ME, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC.
    Arthritis Rheumatol; 2017 Nov 06; 69(11):2151-2161. PubMed ID: 28805045
    [Abstract] [Full Text] [Related]

  • 12. The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.
    Curtis JR, McInnes IB, Rahman P, Gladman DD, Peterson S, Agarwal P, Yang F, Kollmeier AP, Hsia EC, Shiff NJ, Zhou B, Han C, Shawi M, Tillett W, Mease PJ.
    Adv Ther; 2022 Oct 06; 39(10):4613-4631. PubMed ID: 35947349
    [Abstract] [Full Text] [Related]

  • 13. The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the 'GO-UP' study.
    Athanassiou P, Kotrotsios A, Kallitsakis I, Bounas A, Dimitroulas T, Garyfallos A, Tektonidou MG, Vosvotekas G, Livieratos A, Petrikkou E, Katsifis G.
    Qual Life Res; 2022 May 06; 31(5):1385-1399. PubMed ID: 34839451
    [Abstract] [Full Text] [Related]

  • 14. Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1.
    Kristensen LE, Soliman AM, Papp K, White D, Barcomb L, Lu W, Eldred A, Behrens F.
    Rheumatology (Oxford); 2023 Feb 01; 62(2):629-637. PubMed ID: 35801915
    [Abstract] [Full Text] [Related]

  • 15. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial.
    van der Heijde D, Deodhar A, Braun J, Mack M, Hsu B, Gathany TA, Inman RD, Han C, GO-RAISE investigators.
    J Rheumatol; 2014 Jun 01; 41(6):1095-103. PubMed ID: 24737912
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of Improvement in Skin and Nail Psoriasis in Bio-naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO-VIBRANT Study.
    Mease P, Elaine Husni M, Chakravarty SD, Kafka S, Parenti D, Kim L, Hung Lo K, Hsia EC, Kavanaugh A.
    ACR Open Rheumatol; 2020 Nov 01; 2(11):640-647. PubMed ID: 33073933
    [Abstract] [Full Text] [Related]

  • 17. Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial.
    Kavanaugh A, Husni ME, Harrison DD, Kim L, Lo KH, Noonan L, Hsia EC.
    J Rheumatol; 2019 Jun 01; 46(6):595-602. PubMed ID: 30770519
    [Abstract] [Full Text] [Related]

  • 18. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial.
    Kavanaugh A, van der Heijde D, McInnes IB, Mease P, Krueger GG, Gladman DD, Gómez-Reino J, Papp K, Baratelle A, Xu W, Mudivarthy S, Mack M, Rahman MU, Xu Z, Zrubek J, Beutler A.
    Arthritis Rheum; 2012 Aug 01; 64(8):2504-17. PubMed ID: 22378566
    [Abstract] [Full Text] [Related]

  • 19. The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies.
    Kavanaugh A, Gottlieb A, Morita A, Merola JF, Lin CY, Birt J, Shuler CL, Hufford MM, Thaçi D.
    Ann Rheum Dis; 2019 Sep 01; 78(9):1215-1219. PubMed ID: 31113794
    [Abstract] [Full Text] [Related]

  • 20. Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.
    McInnes IB, Mease PJ, Schett G, Kirkham B, Strand V, Williams N, Fox T, Pricop L, Jugl SM, Gandhi KK, FUTURE 2 Study Group.
    Arthritis Res Ther; 2018 Jun 07; 20(1):113. PubMed ID: 29880010
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.